-
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Share
- Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
- Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”
Contacts
David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86
Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023
Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell
More News From Medincell
Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: UZEDY® U.S. net sales reached $85M in Q3 2026, up 96% year-on-year, according to third-quarter results reported today by Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals (NYSE and TASE: TEVA). Teva raised its 2026 UZEDY® revenue outlook to $290-$310M, from $270-$290M previously. UZEDY® generated $225M in U.S. net sales over the first nine months of 2026, exceeding the $191M reported for full-year 2025. UZEDY® commercial performance in...
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple ther...
Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments acr...
